---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-400213"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2026-09-24T12:10:14+00:00"
generated_at: "2026-09-24T13:03:47.585639+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aptevo advances trispecific candidate APVO451; IND-enabling studies expected 1H2027

## Summary
- Optimizing several trispecific candidates for reliable, scalable manufacturing, a key step toward human testing.
- Lead candidate APVO451 to enter IND-enabling studies in 1H2027.
- Trispecifics combine three functions: recognize cancer, activate immune cells, overcome tumor defenses.
- Aptevo to present additional details at an upcoming international scientific conference.

## SEC filing metadata
- accession: 0001193125-26-400213
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2026-09-24T12:10:14+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000119312526400213/0001193125-26-400213-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000119312526400213/apvo-20260924.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-400213
- JSON: https://secwatch.observer/filing/0001193125-26-400213.json
- Plain text: https://secwatch.observer/filing/0001193125-26-400213.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.